Mantle cell lymphoma: charting disease course across multiple treatment lines

  • Kumar A & al.
  • Blood Cancer J
  • 20.05.2019

  • von David Reilly
  • Univadis Clinical Summaries
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Unmet treatment needs persist for patients with mantle cell lymphoma (MCL) with early treatment failure or who fail multiple lines of therapy.

Why this matters

  • This study is unique in its duration of modern longitudinal data.

Study design

  • Study to investigate outcomes with successive treatment lines in 404 patients with MCL newly diagnosed and followed from 2000 to 2014.
  • Funding: Memorial Sloan Kettering Cancer Center; George L. Ohrstrom Jr Foundation.

Key results

  • Median OS by treatment line:
    • First-line: 116.3 (95% CI, 99.1-145.9) months.
    • Second-line: 41.1 (95% CI, 31.1-54.5) months.
    • Third-line: 25.2 (95% CI, 17.9-33.8) months.
    • Fourth-line: 14.4 (95% CI, 9.2-22.0) months.
  • Median PFS by treatment line:
    • First-line: 47.4 (95% CI, 40.5-56.5) months.
    • Second-line: 14.0 (95% CI, 9.7-16.0) months.
    • Third-line: 6.5 (95% CI, 3.8-10.0) months.
    • Fourth-line: 5.0 (95% CI, 3.0-9.7) months.
  • Median PFS with late first-line treatment failure, 15.7 (95% CI, 13.4-21.0) months vs 9.7 (95% CI, 4.9-15.2) months with early first-line failure (P<.01>
  • Median OS with late first-line treatment failure, 70.4 (95% CI, 41.0-86.4) months vs 29.9 (95% CI, 26.4-41.1) months with early first-line failure (P<.01>

Limitations

  • Ibrutinib received approval in 2013.